While the COVID-19 vaccines introduced many people to RNA-based medicines, RNA oligonucleotides have already been on the market for years to treat diseases like Duchenne Muscular Dystrophy and amyloidosis. RNA therapies offer many advantages over traditional small molecule drugs, including their ability to address almost any genetic component within cells and to guide gene editing tools like CRISPR to their targets.
